ClinicalTrials.gg
WithdrawnNCT05828303Updated Apr 1, 2025

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

A Phase 1 interventional study of TPX-0005 and Metformin Hydrochloride in Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Turning Point Therapeutics, Inc.. Withdrawn at 33 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.

Sponsored by Turning Point Therapeutics, Inc. (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Insufficient enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 1 of them phase 3. Neoplasm Metastasis · Bristol-Myers Squibb.

Enrollment
43rd of 44
0 · median 66
Started
2024
with 1 other
Phase 1
16 of 50
none open now
Registered
46th of 50
by date

Among the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, this one is the 43rd largest by enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2024, is one of 16 in phase 1, and was the 46th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb is open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Neoplasm Metastasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is a Phase 1 study to evaluate the potential drug-drug interaction (DDI) effect of repotrectinib on certain drug transporters in patients with advanced cancer.

Read the detailed description

This is a Phase 1, open-label, fixed-sequence study to evaluate the potential drug-drug interaction (DDI) effect of repotrectinib on drug transporters (metformin, digoxin and rosuvastatin) following multiple dose administration of repotrectinib in patients with advanced cancer harboring ROS1 and NTRK1 Rearrangements.

03

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. or cytologically confirmed diagnosis of locally advanced, or solid tumor (including primary central nervous system [CNS] tumors) that harbors a ROS1 or NTRK1-3 gene fusion.
  2. Patient must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing.
  3. Patients must have an (ECOG) Performance Status 0-2 (≥ 18 years).
  4. Protocol specified baseline hematology, liver function and kidney function laboratory values.

Key Exclusion Criteria:

  1. Concurrent participation in another therapeutic clinical trial.
  2. Symptomatic or .
  3. Major surgery within 4 weeks of start of repotrectinib treatment.
  4. cardiovascular disease.
  5. History of non-pharmacologically induced prolonged
  6. Known active infections requiring ongoing treatment (bacterial, fungal, viral including positivity).
  7. Gastrointestinal disease or other malabsorption syndromes.
  8. Current or anticipated use of drugs that are known to be moderate or strong inhibitors or inducers.
  9. Patients who have received, or are expected to receive metformin, digoxin or rosuvastatin within 14 days prior to beginning of the DDI assessment period.
  10. Patients who have received or are expected to receive drugs that are inhibitors of P-gp, OATP1B1, BCRP, and MATE2-K within 14 days or 5 half-lives (whichever is longer) prior to beginning of the DDI assessment period until the DDI assessment period is completed.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Repotrectinib (TPX-0005)

    Phase 1 Oral repotrectinib (TPX-0005) + cocktail drugs (metformin hydrochloride, digoxin, rosuvastatin calcium)

    Drug: TPX-0005 · Drug: Metformin Hydrochloride · Drug: Digoxin · Drug: Rosuvastatin Calcium

Interventions

  • Oral TPX-0005 capsules

    Also known as: repotrectinib

  • oral solution

    Also known as: Glucophage, Metabet, Glucient, Diagemet, Axpinet

  • oral tablet

    Also known as: Lanoxin

  • DrugRosuvastatin Calcium

    oral tablet

    Also known as: Crestor

06

What researchers measure

Primary outcomes

  1. Area under plasma-concentration time curve

    AUC0-t: area under the plasma-concentration time curve from time 0 to time of the last measurable concentration. AUC0-inf: area under the plasma-concentration time curve from time 0 to infinity (if data permit).

    Time frame: Within 28 days of first cocktail dose

  2. Maximum Observed Plasma Concentration

    Cmax: maximum observed plasma concentration

    Time frame: Within 28 days of first cocktail dose

Secondary outcomes

  1. Evaluate safety and tolerability

    To evaluate the safety and tolerability of repotrectinib in patients with moderate and severe hepatic impairment and patients with normal hepatic function following single and multiple dose administration of repotrectinib assessed by CTCAE v5.0

    Time frame: Within 28 days of first cocktail dose

07

Study locations

33 sites
  • Gabrail Cancer Research Center
    Canton, Ohio 44718, United States
  • Local Institution - 2101
    Canton, Ohio 44718, United States
  • Local Institution - 2119
    Westmead, New South Wales 2145, Australia
  • Local Institution - 2126
    Botafogo, RJ 22281100, Brazil
  • Local Institution - 2132
    Porto Alegre, RS 90050-170, Brazil
  • Local Institution - 2134
    Porto Alegre, RS 90610-000, Brazil
  • Local Institution - 2130
    Sao Paulo, SP 1308050, Brazil
  • Local Institution - 2108
    Sao Paulo, 01246-000, Brazil
  • Local Institution - 2123
    Bordeaux, 33076, France
  • Local Institution - 2122
    La Tronche, 38700, France
  • Local Institution - 2117
    Marseille, 13915, France
  • Local Institution - 2115
    Nantes, 44093, France
  • Local Institution - 2121
    Poitiers, 86021, France
  • Local Institution - 2136
    Rennes, 35000, France
  • Local Institution - 2120
    Saint-Herblain, 44805, France
  • Local Institution - 2135
    Milan, MI 20132, Italy
  • Local Institution - 2116
    Rozzano, MI 20089, Italy
  • Local Institution - 2111
    Perugia, PG 06129, Italy
  • Local Institution - 2104
    Aviano, PN 33081, Italy
  • Local Institution - 2103
    Verona, VR 37134, Italy
  • Local Institution - 2114
    Naples, 80131, Italy
  • Local Institution - 2124
    Barcelona, B 08003, Spain
  • Local Institution - 2113
    Barcelona, B 08025, Spain
  • Local Institution - 2105
    Barcelona, B 8035, Spain
  • Local Institution - 2129
    Pozuelo de Alarcon, Madrid 28223, Spain
  • Local Institution - 2138
    Madrid, M 28027, Spain
  • Local Institution - 2110
    Madrid, M 28034, Spain
  • Local Institution - 2128
    Madrid, M 28040, Spain
  • Local Institution - 2109
    Barcelona, 8950, Spain
  • Local Institution - 2127
    Madrid, 28033, Spain
  • Local Institution - 2106
    Madrid, 28040, Spain
  • Local Institution - 2112
    Pamplona, 31008, Spain
  • Local Institution - 2125
    Valencia, 46009, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Jul 2025, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2023
First posted
Apr 25, 2023
StartEst.
Nov 15, 2024
Primary completionEst.
Jul 31, 2025
CompletionEst.
Nov 30, 2025
Last update
Apr 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05828303
Responsible party
Sponsor
First posted
Apr 25, 2023
Start date
Nov 15, 2024 (estimated)
Primary completion
Jul 31, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Apr 1, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repotrectinib

Start the discussion